84 related articles for article (PubMed ID: 17697546)
1. [Correlation of cyclooxygenase-2 expression to P-glycoprotein expression in B-cell non-Hodgkin's lymphoma].
Li B; Zhong MZ; Tang TF; Liu W; Huang J
Ai Zheng; 2007 Aug; 26(8):851-5. PubMed ID: 17697546
[TBL] [Abstract][Full Text] [Related]
2. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma.
Bedewy AM; Elgammal MM; Bedewy MM; El-Maghraby SM
Ann Hematol; 2013 Oct; 92(10):1359-67. PubMed ID: 23652586
[TBL] [Abstract][Full Text] [Related]
3. [Expression of survivin and P63 protein in B cell non-Hodgkin's lymphoma and their effects on cell apoptosis and proliferation].
Zuo XL; Zhou Y; Zhou X; Liu XH; Zhang KJ; Yang HQ; Meng J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):99-102. PubMed ID: 17490531
[TBL] [Abstract][Full Text] [Related]
4. [Expression and significance of P-gp/mdr1 mRNA, MRP and LRP in non-Hodgkin's lymphoma].
Li L; Su LP; Ma L; Zhao J; Zhu L; Zhou YA
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):199-202. PubMed ID: 19615260
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 expression in non-Hodgkin's lymphomas.
Paydas S; Ergin M; Erdogan S; Seydaoglu G
Leuk Lymphoma; 2007 Feb; 48(2):389-95. PubMed ID: 17325901
[TBL] [Abstract][Full Text] [Related]
6. COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis.
Gallouet AS; Travert M; Bresson-Bepoldin L; Guilloton F; Pangault C; Caulet-Maugendre S; Lamy T; Tarte K; Guillaudeux T
Clin Cancer Res; 2014 May; 20(10):2663-73. PubMed ID: 24637636
[TBL] [Abstract][Full Text] [Related]
7. Density of intranodal lymphatics and VEGF-C expression in B-cell lymphoma and reactive lymph nodes.
Wróel T; Mazur G; Dziegiel P; Jeleń M; Szuba A; Kuliczkowski K; Zabel M
Folia Histochem Cytobiol; 2006; 44(1):43-7. PubMed ID: 16584091
[TBL] [Abstract][Full Text] [Related]
8. Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma.
Hess G; Flohr T; Kolbe K; Bonn S; Schuler M; Derigs HG; Huber C
Ann Hematol; 2006 Nov; 85(11):769-79. PubMed ID: 16896912
[TBL] [Abstract][Full Text] [Related]
9. [Expression and clinical significance of mdr-1 gene in lymphoma].
Tian WH; Feng HL; Gao JS; Jiang WQ
Ai Zheng; 2002 Aug; 21(8):910-3. PubMed ID: 12478906
[TBL] [Abstract][Full Text] [Related]
10. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
11. High expression of MDR-1 gene and P-glycoprotein in initial and re-biopsy specimens of relapsed B-cell lymphoma.
Liu Q; Ohshima K; Kikuchi M
Histopathology; 2001 Mar; 38(3):209-16. PubMed ID: 11260300
[TBL] [Abstract][Full Text] [Related]
12. Ligustrazine as a salvage agent for patients with relapsed or refractory non-Hodgkin's lymphoma.
Yang XG; Jiang C
Chin Med J (Engl); 2010 Nov; 123(22):3206-11. PubMed ID: 21163116
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
[TBL] [Abstract][Full Text] [Related]
14. [Protein expressions of Fas and FasL in B-cell lymphoma and their significances].
Jin Y; Li YC; Su ZL; Tang LY; Feng ZY; Guo SZ
Ai Zheng; 2005 Mar; 24(3):332-6. PubMed ID: 15757536
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism.
Zatelli MC; Luchin A; Piccin D; Tagliati F; Bottoni A; Vignali C; Bondanelli M; degli Uberti EC
J Clin Endocrinol Metab; 2005 Oct; 90(10):5754-60. PubMed ID: 16091477
[TBL] [Abstract][Full Text] [Related]
16. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
17. Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients.
Inaoka RJ; Jungbluth AA; Gnjatic S; Ritter E; Hanson NC; Frosina D; Tassello J; Etto LY; Bortoluzzo AB; Alves AC; Colleoni GW
Cancer Immunol Immunother; 2012 Dec; 61(12):2207-14. PubMed ID: 22638551
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
19. [Expressions and significance of COX-2 and P-gp in human hepatocellular carcinoma tissues].
Li B; Liu Y; Su S; Zhang MY; Yuan Q; Chen C; Xia XM; Liu CA; Gong JP
Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):755-8. PubMed ID: 22409848
[TBL] [Abstract][Full Text] [Related]
20. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
